FREE Top 5 ASX Stocks for October 2026 Download Free Report
ASX 200

Checkout Our Recommendation for free - 7 days free trial

Subscribe Now
ASX:1AD

Adalta Ltd - 1AD share price

$ - -
-

About Adalta Ltd

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with GE Healthcare to discover i-bodies against granzyme B for use as a molecular imaging agent. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.

Company Profile

Market Cap -
Book Value -

Enterprise Value -
Revenue TTM -

Shares Outstanding -
Earning Share -

Shares Float -
Dividend per Share -

P/E Ratio -
Div Yield -

Disclaimer: The above financial data is sourced from EODHD and is for informational purposes only. Veye does not guarantee the accuracy or completeness of this data. Investors should conduct their own research and consult with a financial advisor before making investment decisions.

Price Summary

Today's Low Today's High
- -
52 Week High
-
52 Week Low
-
Limited Offer
Try Veye Free for 7 Days

Expert ASX stock picks, in-depth research & buy/sell signals — free for a full week.

Start Free Trial

No credit card required

Price Chart (1AD)

TOP ASX STOCKS Worth Watching

  • ✓ Instant Access
  • ✓ No Credit Card Required
  • ✓ Free to join · No spam
Get Free Report on WhatsApp

Free to join · No spam · Unsubscribe anytime

By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.

Special Research Report

Discover the Top ASX Stocks to Invest in 2026!

Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...